This fall, tens of millions of Americans will get vaccinated against influenza, but they won’t all experience a prick in the arm. Instead, many will take FluMist, the painless nasal flu vaccine. FluMist is just one of many breakthrough innovations that originated at the University of Michigan, where I served as Managing Director of Licensing within the Office of Tech Transfer for over a decade. I now serve as Executive Director of Duke University’s Office of Licensing & Ventures which has a similar portfolio of innovations including Krystexxa, a treatment for refractory gout. Over my many years at three universities, I’ve seen countless,